| Literature DB >> 30335774 |
Andrew M Scheidler1, Dominique Kinnett-Hopkins1, Yvonne C Learmonth1, Robert Motl1, Citlali López-Ortiz1,2.
Abstract
BACKGROUND: Multiple sclerosis (MS) is a disease of the central nervous system that causes ataxia and deficits in balance. Exercise-based therapies have been identified as integral to the recovery of motor function in MS, but few studies have investigated non-traditional movement interventions. We examined a targeted ballet program (TBP) designed to mitigate ataxia and improve balance in females with mild-to-moderate relapsing-remitting MS. METHODS ANDEntities:
Mesh:
Year: 2018 PMID: 30335774 PMCID: PMC6193654 DOI: 10.1371/journal.pone.0205382
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1TREND flow diagram.
Description of study population recruitment.
Participant socio-demographic information.
| Subject | Age | Gender | Race | Education | Economic activity | Type of MS | EDSS | SDMT Score | Assistive Devices | Previous Dance Training |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 58 | F | White | >14 years | No | RRMS | 5.5 | 52 | Cane ≥100m walk | None |
| 2 | 50 | F | White | >14 years | No | RRMS | 5 | 49 | Cane ≥200m walk | None |
| 3 | 60 | F | White | >14 years | No | RRMS | 4.5 | 60 | Cane ≥300m walk | None |
| 4 | 65 | F | White | >14 years | No | RRMS | 6.5 | 43 | Walker ≥20m | None |
| 5 | 57 | F | White | >14 years | No | RRMS | 6 | 37 | Cane ≥100m walk/motor wheelchair | None |
| 6 | 54 | F | Black | >14 years | No | RRMS | 5.5 | 63 | Cane ≥100m walk/Right ankle dorsiflexor | None |
| 7 | 48 | F | White | >14 years | No | RRMS | 3 | 44 | None | None |
| 8 | 36 | F | White | >14 years | Yes | RRMS | 2.5 | 44 | None | None |
Fig 2Marker landmarks.
Anatomical landmarks for reflective marker placement.
Quantitative outcome measures.
| PARTICIPANT | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Mean | SD | P-Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.15 | -65.68 | -72.04 | -100.9 | -83.7 | -71.85 | -83.66 | -71.85 | ||||
| -73.06 | -66.25 | -71.77 | -86.1 | -84.64 | -64.85 | -68.34 | -70.46 | ||||
| -74.62 | -65.78 | -70.9 | -102.7 | -84.85 | -90.83 | -81.42 | -82.81 | ||||
| -70.32 | -65.64 | -75.41 | -86.45 | -84.89 | -85.22 | -66.62 | -65.75 | ||||
| -0.36 | -5.79 | -0.50 | -5.45 | -0.26 | 0.00 | -8.98 | -10.93 | ||||
| -29.66 | -9.53 | -2.48 | -8.15 | -29.67 | -63.89 | -10.45 | -4.96 | ||||
| -0.11 | -6.52 | -15.06 | -0.54 | -11.12 | 0.00 | -11.80 | -6.82 | ||||
| -0.77 | -7.01 | -0.99 | -5.51 | -24.31 | -6.45 | -12.94 | -6.20 | ||||
| -0.59 | -1.35 | -4.24 | -2.75 | -1.02 | 0.00 | -26.75 | -33.74 | ||||
| -21.17 | -11.41 | -10.90 | -2.89 | -39.31 | -0.71 | -9.46 | -5.78 | ||||
| -0.56 | -2.76 | -21.61 | -0.28 | -0.09 | 0.00 | -8.55 | -4.72 | ||||
| -41.42 | -9.10 | -14.06 | -18.37 | -5.64 | -21.75 | -15.69 | -9.99 | ||||
Actual measured values for all quantitative tests across all participants. One of the participants was unable to complete the postural stability from taking a step pre-assessment: thus, the global balance measure (GBM) before the intervention was equal to zero. Following the intervention, the same participant was then able to complete the task in all four directions.
*A Wilcoxon signed-rank test was conducted instead of a single-tailed paired t-test.
Fig 3Center of pressure velocity decay.
A typical example of exponential fits to the center of pressure velocity (COPV) before and after the TBP for participant 8. A stronger GBM is demonstrated in the Post-TBP backwards direction (lower graph) with a sharper deceleration. Pre-TBP and Post-TBP GBM values for these graphs equal -4.72 and -9.99, respectively; indicating faster stabilization from dynamic to static balance.
Clinical outcome measures.
| PARTICIPANT | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Mean | SD | P-value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 21 | 11 | 11 | 16 | 16 | 17 | 27 | ||||
| 20 | 26 | 24 | 22 | 21 | 22 | 26 | 28 | ||||
| 10 | 7 | 12 | 16 | 9 | 9 | 3 | 3 | ||||
| 6 | 2 | 6 | 11 | 2 | 6.5 | 0 | 1 | ||||
| 18 | 11 | 7 | 8 | 6 | 17 | 11 | 4 | ||||
| 13 | 1 | 3 | 5 | 0 | 6.5 | 0 | 2 | ||||
| 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | ||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | ||||
| 28 | 18 | 19 | 24 | 18 | 27 | 16 | 7 | ||||
| 19 | 3 | 9 | 16 | 2 | 13 | 0.5 | 3 | ||||
Actual measured values for clinical tests across all participants.